| Year |
Citation |
Score |
| 2018 |
Stump S, Mou TC, Sprang SR, Natale NR, Beall HD. Crystal structure of the major quadruplex formed in the promoter region of the human c-MYC oncogene. Plos One. 13: e0205584. PMID 30312328 DOI: 10.1371/Journal.Pone.0205584 |
0.317 |
|
| 2015 |
Weaver MJ, Kearns AK, Stump S, Li C, Gajewski MP, Rider KC, Backos DS, Reigan PR, Beall HD, Natale NR. AIMing towards improved antitumor efficacy. Bioorganic & Medicinal Chemistry Letters. 25: 1765-70. PMID 25782743 DOI: 10.1016/J.Bmcl.2015.02.063 |
0.735 |
|
| 2014 |
Duncan NS, Beall HD, Kearns AK, Li C, Natale NR. Ethyl 3-(9-chloro-10-oxo-9,10-di-hydro-anthracen-9-yl)-5-methyl-isoxazole-4-carboxyl-ate. Acta Crystallographica. Section E, Structure Reports Online. 70: o315-6. PMID 24765016 DOI: 10.1107/S1600536814003080 |
0.711 |
|
| 2013 |
Newsome JJ, Hassani M, Swann E, Bibby JM, Beall HD, Moody CJ. Benzofuran-, benzothiophene-, indazole- and benzisoxazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1. Bioorganic & Medicinal Chemistry. 21: 2999-3009. PMID 23635904 DOI: 10.1016/J.Bmc.2013.03.071 |
0.77 |
|
| 2013 |
Keyari CM, Kearns AK, Duncan NS, Eickholt EA, Abbott G, Beall HD, Diaz P. Synthesis of new quinolinequinone derivatives and preliminary exploration of their cytotoxic properties. Journal of Medicinal Chemistry. 56: 3806-19. PMID 23574193 DOI: 10.1021/Jm301689X |
0.765 |
|
| 2012 |
Mirzaei YR, Weaver MJ, Steiger SA, Kearns AK, Gajewski MP, Rider KC, Beall HD, Natale NR. Improved synthesis of 3-aryl isoxazoles containing fused aromatic rings. Tetrahedron. 68: 10360-10364. PMID 23526841 DOI: 10.1016/J.Tet.2012.09.084 |
0.724 |
|
| 2012 |
Kearns AK, Gajewski MP, Natale NR, Beall HD. Abstract 1767: Anthracenyl isoxazole amides (AIMs) as novel agents for brain tumors Cancer Research. 72: 1767-1767. DOI: 10.1158/1538-7445.Am2012-1767 |
0.74 |
|
| 2010 |
Cai W, Hassani M, Karki R, Walter ED, Koelsch KH, Seradj H, Lineswala JP, Mirzaei H, York JS, Olang F, Sedighi M, Lucas JS, Eads TJ, Rose AS, Charkhzarrin S, ... ... Beall HD, et al. Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents. Bioorganic & Medicinal Chemistry. 18: 1899-909. PMID 20149966 DOI: 10.1016/J.Bmc.2010.01.037 |
0.767 |
|
| 2009 |
Gajewski MP, Beall H, Schnieder M, Stranahan SM, Mosher MD, Rider KC, Natale NR. Bis-anthracenyl isoxazolyl amides have enhanced anticancer activity. Bioorganic & Medicinal Chemistry Letters. 19: 4067-9. PMID 19560922 DOI: 10.1016/J.Bmcl.2009.06.019 |
0.353 |
|
| 2008 |
Hassani M, Cai W, Koelsch KH, Holley DC, Rose AS, Olang F, Lineswala JP, Holloway WG, Gerdes JM, Behforouz M, Beall HD. Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies. Journal of Medicinal Chemistry. 51: 3104-15. PMID 18457384 DOI: 10.1021/Jm701066A |
0.768 |
|
| 2007 |
Newsome JJ, Colucci MA, Hassani M, Beall HD, Moody CJ. Benzimidazole- and benzothiazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1. Organic & Biomolecular Chemistry. 5: 3665-73. PMID 17971996 DOI: 10.1039/B713044A |
0.769 |
|
| 2007 |
Newsome JJ, Swann E, Hassani M, Bray KC, Slawin AM, Beall HD, Moody CJ. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Organic & Biomolecular Chemistry. 5: 1629-40. PMID 17571194 DOI: 10.1039/B703370B |
0.787 |
|
| 2007 |
Pereira FE, Coffin JD, Beall HD. Activation of protein kinase C and disruption of endothelial monolayer integrity by sodium arsenite--Potential mechanism in the development of atherosclerosis. Toxicology and Applied Pharmacology. 220: 164-77. PMID 17306850 DOI: 10.1016/J.Taap.2006.12.035 |
0.714 |
|
| 2006 |
Bunderson M, Pereira F, Schneider MC, Shaw PK, Coffin JD, Beall HD. Manganese enhances peroxynitrite and leukotriene E4 formation in bovine aortic endothelial cells exposed to arsenic. Cardiovascular Toxicology. 6: 15-23. PMID 16845179 DOI: 10.1385/Ct:6:1:15 |
0.717 |
|
| 2005 |
Hassani M, Cai W, Holley DC, Lineswala JP, Maharjan BR, Ebrahimian GR, Seradj H, Stocksdale MG, Mohammadi F, Marvin CC, Gerdes JM, Beall HD, Behforouz M. Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1. Journal of Medicinal Chemistry. 48: 7733-49. PMID 16302813 DOI: 10.1021/Jm050758Z |
0.786 |
|
| 2004 |
Bunderson M, Brooks DM, Walker DL, Rosenfeld ME, Coffin JD, Beall HD. Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicology and Applied Pharmacology. 201: 32-9. PMID 15519606 DOI: 10.1016/J.Taap.2004.04.008 |
0.748 |
|
| 2004 |
Fryatt T, Pettersson HI, Gardipee WT, Bray KC, Green SJ, Slawin AM, Beall HD, Moody CJ. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1). Bioorganic & Medicinal Chemistry. 12: 1667-87. PMID 15028260 DOI: 10.1016/J.Bmc.2004.01.021 |
0.451 |
|
| 2002 |
Whatmore JL, Swann E, Barraja P, Newsome JJ, Bunderson M, Beall HD, Tooke JE, Moody CJ. Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents. Angiogenesis. 5: 45-51. PMID 12549859 DOI: 10.1023/A:1021528628524 |
0.751 |
|
| 2002 |
Bunderson M, Coffin JD, Beall HD. Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicology and Applied Pharmacology. 184: 11-8. PMID 12392964 DOI: 10.1006/Taap.2002.9492 |
0.754 |
|
| 2001 |
Swann E, Barraja P, Oberlander AM, Gardipee WT, Hudnott AR, Beall HD, Moody CJ. Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2. Journal of Medicinal Chemistry. 44: 3311-9. PMID 11563930 DOI: 10.1021/Jm010884C |
0.454 |
|
| 2000 |
Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chemico-Biological Interactions. 129: 77-97. PMID 11154736 DOI: 10.1016/S0009-2797(00)00199-X |
0.317 |
|
| 2000 |
Beall HD, Winski SI. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development. Frontiers in Bioscience : a Journal and Virtual Library. 5: D639-48. PMID 10877993 DOI: 10.2741/Beall |
0.323 |
|
| 1999 |
Fryatt T, Goroski DT, Nilson ZD, Moody CJ, Beall HD. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1). Bioorganic & Medicinal Chemistry Letters. 9: 2195-8. PMID 10465544 DOI: 10.1016/S0960-894X(99)00369-8 |
0.442 |
|
| 1998 |
Beall HD, Hudnott AR, Winski S, Siegel D, Swann E, Ross D, Moody CJ. Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1. Bioorganic & Medicinal Chemistry Letters. 8: 545-8. PMID 9871615 DOI: 10.1016/S0960-894X(98)00069-9 |
0.327 |
|
| 1998 |
Beall HD, Winski S, Swann E, Hudnott AR, Cotterill AS, O'Sullivan N, Green SJ, Bien R, Siegel D, Ross D, Moody CJ. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. Journal of Medicinal Chemistry. 41: 4755-66. PMID 9822546 DOI: 10.1021/Jm980328R |
0.363 |
|
| 1992 |
Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, Ross D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry. 31: 7879-85. PMID 1510975 DOI: 10.1021/Bi00149A019 |
0.302 |
|
| Show low-probability matches. |